<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01541891</url>
  </required_header>
  <id_info>
    <org_study_id>COXAVSSY0311FII</org_study_id>
    <secondary_id>PRO-148</secondary_id>
    <nct_id>NCT01541891</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome</brief_title>
  <acronym>PRO-148</acronym>
  <official_title>Fase II Comparative Study of the Efficacy and Safety of PRO-148 Ophthalmic Solution vs Systane in the Treatment of Mild-to-moderate Eye Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Sophia S.A de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Sophia S.A de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of PRO-148 ophthalmic
      solution compared with SYSTANE ® ophthalmic solution for the treatment of signs and symptoms
      of mild-to-moderate dry eye syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 2, randomized, double masked clinical, parallel-group clinical trial to evaluate the
      efficacy and safety of PRO-148 ophthalmic solution compared with SYSTANE ® ophthalmic
      solution for the treatment of signs and symptoms of mild-to-moderate dry eye syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tear Film Break-up Time (TBUT)</measure>
    <time_frame>During 60 days</time_frame>
    <description>TBUT was evaluated at baseline and end of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of Adverse Events</measure>
    <time_frame>60 days</time_frame>
    <description>The presence of adverse events will be reported in both treatment arms. This variable will be reported by the number of events presented.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of Visual Acuity</measure>
    <time_frame>60 days</time_frame>
    <description>The LogMAR scale evaluates the visual acuity of subjects with a logarithmic scale where base 0 is the best visual acuity and 1 is the worst. This variable will be reported with means for comparison between groups.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>PRO-148 Ophthalmic Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: PRO-148 Intervention name: PRO-148 applied in ocular surface of patients with mild to moderate dry eye syndrome q.i.d. for 60 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B. SYSTANE® Ophthalmic Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: SYSTANE® Intervention name: SYSTANE® applied in ocular surface of patients with mild to moderate dry eye syndrome q.i.d. for 60 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO-148 Ophthalmic Solution</intervention_name>
    <description>PRO-148 Ophthalmic Solution applied four times per day (c/6 hours) during 60 days.</description>
    <arm_group_label>PRO-148 Ophthalmic Solution</arm_group_label>
    <other_name>PRO-148</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator: SYSTANE ® Ophthalmic Solution</intervention_name>
    <description>Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.</description>
    <arm_group_label>Arm B. SYSTANE® Ophthalmic Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnosis of mild-to-moderate drye eye syndrome.

          -  Male or female patients.

          -  Patients 18 years of age

        Exclusion Criteria:

          -  Patients with one blind eye.

          -  Visual acuity of 20/40 in any eye

          -  Patients with history of active stage of any other concomitant ocular disease.

          -  Patients taking any medication, topically or by any other route, which could interfere
             with the study's results, in the 3 days prior to trial or until a time period in which
             residual effects could be present.

          -  Contraindications or sensitivity to any component of the study treatments.

          -  Ocular surgery within the past 3 months.

          -  Contact lens users.

          -  Females of childbearing potential )may not participate in the study if any of the
             following conditions exist:

               -  They are pregnant,

               -  They are breastfeeding,

               -  They have a positive urine pregnancy test at screening,

               -  They intend to become pregnant during the study, or

               -  They do not agree to use adequate birth control methods for the duration of the
                  study.

          -  Participation in any studies of investigational drugs within 90 days previous to the
             inclusion.

        Discontinuation criteria:

          -  Patients could be discontinued before the completion of the study because of adverse
             events, pregnancy, protocol violations, lack of efficacy, or administrative reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José F Alaniz-De La O, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antiguo Hospital Civil de Guadalajara &quot;Fray Antonio Alcalde&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura R Saucedo-Rodíguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antiguo Hospital Civil de Guadalajara &quot;Fray Antonio Alcalde&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leopoldo M Baiza-Durán, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Research Department. Laboratorios Sophia SA de CV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antiguo Hospital Civil de Guadalajara &quot;Fray Antonio Alcalde&quot;</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2012</study_first_posted>
  <results_first_submitted>June 3, 2013</results_first_submitted>
  <results_first_submitted_qc>February 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2018</results_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PRO-148</keyword>
  <keyword>Dry eye syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>30 patients were enrolled in this study at 1 hospital</recruitment_details>
      <pre_assignment_details>Elegible patients were de novo patients diagnosed with mild to moderate dry eye disease</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A PRO 148 Ophthalmic Solution</title>
          <description>PRO-148 Ophthalmic Solution : PRO-148 Ophthalmic Solution applied four times per day (c/6 hours) during 60 days.</description>
        </group>
        <group group_id="P2">
          <title>Arm B. SYSTANE® Ophthalmic Solution</title>
          <description>Active Comparator: SYSTANE ® Ophthalmic Solution : Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>14 patients of each group were included in the analysis (28 i total), the other 2 patients (1 of each group) were excluded due to lack of follow-up</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A PRO 148 Ophthalmic Solution</title>
          <description>PRO-148 Ophthalmic Solution : PRO-148 Ophthalmic Solution applied four times per day (c/6 hours) during 60 days.</description>
        </group>
        <group group_id="B2">
          <title>Arm B. SYSTANE® Ophthalmic Solution</title>
          <description>Active Comparator: SYSTANE ® Ophthalmic Solution : Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.8" spread="8.4"/>
                    <measurement group_id="B2" value="55.9" spread="9.6"/>
                    <measurement group_id="B3" value="55.8" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tear Film Break-up Time (TBUT)</title>
        <description>TBUT was evaluated at baseline and end of the study</description>
        <time_frame>During 60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A PRO 148 Ophthalmic Solution</title>
            <description>PRO-148 Ophthalmic Solution : PRO-148 Ophthalmic Solution applied four times per day (c/6 hours) during 60 days.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. SYSTANE® Ophthalmic Solution</title>
            <description>Active Comparator: SYSTANE ® Ophthalmic Solution : Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Film Break-up Time (TBUT)</title>
          <description>TBUT was evaluated at baseline and end of the study</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="2.3"/>
                    <measurement group_id="O2" value="4.7" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of the study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="2.5"/>
                    <measurement group_id="O2" value="7.3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Adverse Events</title>
        <description>The presence of adverse events will be reported in both treatment arms. This variable will be reported by the number of events presented.</description>
        <time_frame>60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A PRO 148 Ophthalmic Solution</title>
            <description>PRO-148 Ophthalmic Solution : PRO-148 Ophthalmic Solution applied four times per day (c/6 hours) during 60 days.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. SYSTANE® Ophthalmic Solution</title>
            <description>Active Comparator: SYSTANE ® Ophthalmic Solution : Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Adverse Events</title>
          <description>The presence of adverse events will be reported in both treatment arms. This variable will be reported by the number of events presented.</description>
          <units>number of cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Evaluation of Visual Acuity</title>
        <description>The LogMAR scale evaluates the visual acuity of subjects with a logarithmic scale where base 0 is the best visual acuity and 1 is the worst. This variable will be reported with means for comparison between groups.</description>
        <time_frame>60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRO-148</title>
            <description>Drug: PRO-148 Intervention name: PRO-148 applied in ocular surface of patients with mild to moderate dry eye syndrome
PRO-148 Ophthalmic Solution: PRO-148 Ophthalmic Solution applied four times per day (c/6 hours) during 60 days.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. SYSTANE® Ophthalmic Solution</title>
            <description>Active Comparator: SYSTANE ® Ophthalmic Solution: Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Visual Acuity</title>
          <description>The LogMAR scale evaluates the visual acuity of subjects with a logarithmic scale where base 0 is the best visual acuity and 1 is the worst. This variable will be reported with means for comparison between groups.</description>
          <units>units on LogMAR scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm A PRO 148 Ophthalmic Solution</title>
          <description>PRO-148 Ophthalmic Solution : PRO-148 Ophthalmic Solution applied four times per day (c/6 hours) during 60 days.</description>
        </group>
        <group group_id="E2">
          <title>Arm B. SYSTANE® Ophthalmic Solution</title>
          <description>Active Comparator: SYSTANE ® Ophthalmic Solution : Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cephalea</sub_title>
                <description>An adverse event was present (mild-intensity cephalea at visit 1 that did not need medications for its relief) in the CS/XG group, but it was not related to the treatment.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All the information is confidential and exclusive property of the sponsor. Information can be revealed only to my staff and regulatory agencies or ethics committee.
All the information from this protocol is confidential and exclusive property of the sponsor, it can not be revealed without written consent from the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Baiza-Duran Leopoldo, Medical Director</name_or_title>
      <organization>Laboratorios Sophia, SA de CV</organization>
      <phone>+52 (33)30014200</phone>
      <email>leopoldo.baiza@sophia.com.mx</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

